Jeong-Chan Lee
Comptroller/Controller/Auditor presso NKMAX CO., LTD.
Provenienza dei contatti di primo grado di Jeong-Chan Lee
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jeong-Chan Lee tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| Korea University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Pharmaceuticals: Other | Chief Executive Officer Director/Board Member | |
| J WAY CO., LTD. | Movies/Entertainment | Chief Executive Officer | |
| TONG YANG LIFE INSURANCE CO., LTD. | Life/Health Insurance | Chief Investment Officer | |
| University of Quebec | College/University | Undergraduate Degree | |
| Wonkwang University | College/University | Undergraduate Degree | |
| Chungnam National University | College/University | Doctorate Degree | |
| PHARMICELL CO., LTD. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Biotechnology | Chief Executive Officer | |
| Nkmax Japan, Inc. | Chief Executive Officer | ||
| Atgen Japan | Chief Executive Officer | ||
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Biotechnology | Chief Executive Officer | |
| Nkmax H&D Co. Ltd. | Chief Executive Officer | ||
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Pharmaceuticals: Major | Chief Executive Officer | |
| ATGen Canada, Inc. | Chief Executive Officer | ||
| ATGen America, Inc. | Chief Executive Officer | ||
| Yonsei University | College/University | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Corea del Sud | 11 |
| Canada | 3 |
| Stati Uniti | 3 |
| Giappone | 3 |
| Thailandia | 2 |
Settori
| Consumer Services | 7 |
| Health Technology | 6 |
| Finance | 2 |
Posizioni
| Chief Executive Officer | 11 |
| Chairman | 10 |
| Director/Board Member | 9 |
| Undergraduate Degree | 5 |
| Founder | 4 |
Contatti più connessi
| Insiders | |
|---|---|
| Sang-Woo Park | 13 |
| Yong-Man Kim | 4 |
| Yong-Hwan Cho | 3 |
| Jun-Yong Song | 3 |
| Kang-Yong Pierre | 2 |
| Jeong-Heon Cha | 2 |
- Borsa valori
- Insiders
- Jeong-Chan Lee
- Connessioni Società
